间羟胺

**间羟胺**
臨床資料
商品名（英语：Drug nomenclature）	Aramine、Metaramin、Pressonex
AHFS/Drugs.com	国际药品名称
核准狀況	美 DailyMed: Metaraminol;
懷孕分級	澳: C ; ;
给药途径	静脉注射、气管内
ATC碼	C01CA09 (WHO) ;
法律規範狀態
法律規範	澳：限医生处方（S4）; 英：处方药（℞-only） (POM); 美：处方药（℞-only）;
藥物動力學數據
生物利用度	n/a
血漿蛋白結合率	~45%
药物代谢	肝
识别信息
	IUPAC命名法 (1R,2S)-3-[-2-amino-1-hydroxy-propyl]phenol; ;
CAS号	54-49-9（; 33402-03-8 (酒石酸氢盐（英语：bitartrate）)）
PubChem CID	5906;
IUPHAR/BPS	7229;
DrugBank	DB00610 ;
ChemSpider	5695 ;
UNII	818U2PZ2EH;
KEGG	D08192 ;
ChEBI	CHEBI:6794 ;
ChEMBL	ChEMBL1201319 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID8023268 ;
化学信息
化学式	C9H13NO2
摩尔质量	167.21 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES O[C@H](c1cc(O)ccc1)[C@@H](N)C;
	InChI InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1 ; Key:WXFIGDLSSYIKKV-RCOVLWMOSA-N ;

间羟胺（INN：metaraminol），以前以Aramine等商品名出售，是间羟基去甲麻黄碱（3,β-二羟基苯丙胺）的立体异构体，是一种有效的拟交感胺，用于预防和治疗低血压，特别是作为并发症麻醉。它是一种α₁-肾上腺素受体激动剂，具有一定的β肾上腺素作用。^[2] 目前Slayback Pharma以通用名来销售该药物。^[3]

用途

间羟胺以推注（通常剂量为0.5-1mg）或输液形式静脉注射（通常通过外周静脉通路）。间羟胺通常以10 mg/mL的形式提供，需要在给药前稀释（通常配制成0.5 mg/mL溶液），但也常见用于快速推注治疗低血压的预制间羟胺注射器。^[4]^[5]

药理学

药效学

间羟胺的血管加压作用的主要机制是间接的，^[6]间羟胺将去甲肾上腺素从神经囊泡中排出，使其发挥血管加压作用。^[7]在较高剂量下，间羟胺可能具有直接的α-肾上腺素激动剂和β₁肾上腺素能激动剂作用。^[6]然而，在临床实践中常见剂量下，间接α₁肾上腺素效应占主导地位，因此反射性心动过缓（英语：Reflex bradycardia）是一种常见的副作用。

研究

间羟胺也用于治疗阴茎异常勃起。^[8]^[9]^[10]

参考资料

^ Injection : Aramine (Metaraminol Bitartrate) (PDF). U.S. Food and Drug Administration (FDA). [12 March 2022]. （原始内容存档 (PDF)于2022-10-22）.
^ Kee VR. Hemodynamic pharmacology of intravenous vasopressors. Crit Care Nurse. Aug 2003, 23 (4): 79–82 [2024-03-30]. PMID 12961786. doi:10.4037/ccn2003.23.4.79. （原始内容存档于2019-08-16）.
^ ANDA Approval for Metaraminol (PDF). United States Food and Drug Administration. 24 August 2021 [13 August 2022]. （原始内容存档 (PDF)于2022-12-06）.
^ Metaraminol 0.5 mg/ml, Solution for Injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk. [2022-10-19]. （原始内容存档于2023-11-08）.
^ Goodrick N, Wentrup T, Messer G, Gleeson P, Culwick M, Goulding G. Pre-filled emergency drugs: The introduction of pre-filled metaraminol and ephedrine syringes into the main operating theatres of a major metropolitan centre. Australasian Anaesthesia. 21 August 2020, (2013): 127–134.
^ ^6.0 ^6.1 Metaraminol. Deranged Physiology. [2022-10-19]. （原始内容存档于2023-12-04）（英语）.
^ Harrison DC, Chidsey CA, Braunwald E. Studies on the Mechanism of Action of Metaraminol (Aramine). Annals of Internal Medicine. September 1963, 59 (3): 297–305. PMID 14065947. doi:10.7326/0003-4819-59-3-297.
^ McDonald M, Santucci R. Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol.. Int Braz J Urol. 2004, 30 (2): 121–2. PMID 15703094. doi:10.1590/S1677-55382004000200007 .
^ Koga S, Shiraishi K, Saito Y. Post-traumatic priapism treated with metaraminol bitartrate: case report.. J Trauma. 1990, 30 (12): 1591–3. PMID 2258979. doi:10.1097/00005373-199012000-00029.
^ Block T, Sturm W, Ernst G, Staehler G, Schmiedt E. [Metaraminol in therapy of various forms of priapism]. Urologe A. 1988, 27 (4): 225–9. PMID 3140463.

外部链接

Metaraminol. Drug Information Portal. U.S. National Library of Medicine. [2024-03-30]. （原始内容存档于2022-09-27）.
Metaraminol bitartrate. Drug Information Portal. U.S. National Library of Medicine. [2024-03-30]. （原始内容存档于2022-05-29）.

[1] Injection : Aramine (Metaraminol Bitartrate) (PDF). U.S. Food and Drug Administration (FDA). [12 March 2022]. （原始内容存档 (PDF)于2022-10-22）.

[3] Kee VR. Hemodynamic pharmacology of intravenous vasopressors. Crit Care Nurse. Aug 2003, 23 (4): 79–82 [2024-03-30]. PMID 12961786. doi:10.4037/ccn2003.23.4.79. （原始内容存档于2019-08-16）.

[4] ANDA Approval for Metaraminol (PDF). United States Food and Drug Administration. 24 August 2021 [13 August 2022]. （原始内容存档 (PDF)于2022-12-06）.

[5] Metaraminol 0.5 mg/ml, Solution for Injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk. [2022-10-19]. （原始内容存档于2023-11-08）.

[6] Goodrick N, Wentrup T, Messer G, Gleeson P, Culwick M, Goulding G. Pre-filled emergency drugs: The introduction of pre-filled metaraminol and ephedrine syringes into the main operating theatres of a major metropolitan centre. Australasian Anaesthesia. 21 August 2020, (2013): 127–134.

[:0-7] 6.0 ^6.1 Metaraminol. Deranged Physiology. [2022-10-19]. （原始内容存档于2023-12-04）（英语）.

[pmid14065947-8] Harrison DC, Chidsey CA, Braunwald E. Studies on the Mechanism of Action of Metaraminol (Aramine). Annals of Internal Medicine. September 1963, 59 (3): 297–305. PMID 14065947. doi:10.7326/0003-4819-59-3-297.

[McDonald-9] McDonald M, Santucci R. Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol.. Int Braz J Urol. 2004, 30 (2): 121–2. PMID 15703094. doi:10.1590/S1677-55382004000200007 .

[Koga-10] Koga S, Shiraishi K, Saito Y. Post-traumatic priapism treated with metaraminol bitartrate: case report.. J Trauma. 1990, 30 (12): 1591–3. PMID 2258979. doi:10.1097/00005373-199012000-00029.

[Block-11] Block T, Sturm W, Ernst G, Staehler G, Schmiedt E. [Metaraminol in therapy of various forms of priapism]. Urologe A. 1988, 27 (4): 225–9. PMID 3140463.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]